Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
about
Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapySyk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemiaFLT3-ITD and its current role in acute myeloid leukaemia.The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.The target landscape of clinical kinase drugs.FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
P2860
Q26796514-5612454F-CE09-4229-8DA2-5E62F4301175Q26799596-7C164789-8465-4C6F-A402-616747B48773Q37313816-26DFE2D7-AB21-4801-AEF0-068301E3DA24Q37362603-8597773A-4472-4619-B869-95E368FB9C28Q37638749-B6E3E7B1-BDD5-483D-B887-32B4ADBF025CQ38756560-D8D7A373-ED40-432E-AA0D-D5845300428EQ38892684-956EB7BD-4374-4046-A8D2-4CF3EEACC4C0Q39282600-B46C7CE6-8247-41DC-9450-E312D41165EBQ42534044-C0CF8B95-61AB-47DE-865E-A01ED6CFF8BFQ47345032-70386AE1-2603-4099-A101-79F5DBF46588Q52366350-7DE98600-D9C6-435C-A969-051D0D9BF870Q52571251-31A6A65A-DAF8-4538-B8C0-63743D9F2E74Q57483591-1BCA0607-0949-483E-A4F1-A75A802AE355
P2860
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@ast
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@en
type
label
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@ast
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@en
prefLabel
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@ast
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@en
P2093
P2860
P50
P1433
P1476
Activating FLT3 mutants show d ...... sis in acute myeloid leukemia.
@en
P2093
Bernhard J Woermann
Daniela Schumacher
Friederike Pastore
Hanna Janke
Harald Polzer
Karsten Spiekermann
Marion Subklewe
Stephanie Schneider
Thomas Büchner
Wolfgang E Berdel
P2860
P304
P356
10.1371/JOURNAL.PONE.0089560
P407
P577
2014-03-07T00:00:00Z